Clinical oncology publications

The purpose of this guidance is to raise awareness of the spleen as an organ at risk (OAR) structure and to ensure that, for all patients receiving radiotherapy to the spleen, the risk of resultant functional hyposplenism is assessed and decisions on appropriate management are made if required.

The Royal College of Radiologist’s (RCR) 2016 breast consensus statements made recommendations on hypofractionation. There was consensus, with strong support, that there was no indication to use more than 15 fractions for the breast, chest wall or nodal areas. Following the FAST-Forward trial primary endpoint publication, the following statements were agreed in 2020 are intended to supplement the 2016 statements. The new statements for postoperative radiotherapy for breast cancer hypofraction are: Consensus statement 1: Offer 26 Gray (Gy) in five fractions over one week for whole breast...

The lung cancer statements should serve as a practical stimulus for lung cancer teams to review their current radiotherapy service to ensure that they are able to deliver optimal treatment for their patients. They should be adopted in parallel with those in the National Institute for Health and Care Excellence (NICE) lung cancer guideline.

This document outlines the responsibilities of the clinicians involved in the delivery of radionuclide therapy across a range of clinical indications.